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THE EXACT-PRO INITIATIVE: DEVELOPMENT AND
VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME
MEASURE FOR EVALUATING EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
Leidy NK,Wilcox TK, Roberts L,Winnette RM, Murray L
United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: To develop and validate a patient-reported
outcome (PRO) instrument for measuring frequency, severity,
and duration of COPD exacerbations in international trials.
METHODS: Multi-sponsor initiative involving experts and the
FDA. Phase I: Instrument development informed by literature
and qualitative data from focus groups and interviews with U.S.
COPD patients. International experts addressed concept rel-
evance, transferability, translation ease. Phase II: Prospective,
2-group, observational study of patients with 1) conﬁrmed exac-
erbation (PDA diary Days 1–28 and 60–67) or 2) stable COPD
(PDA for 7 days). Item analyses and Rasch IRT were used to
reduce the items from 23 to 14. Validity testing included known-
group differences and relationship to clinical history, SGRQ-C,
and clinician and patient assessment of exacerbation severity.
RESULTS: Phase I: N = 83; 45% male; 16% African American;
13% Hispanic; mean age = 65 (10); stable FEV-1 = 44% pred
(16). Phase II: N 410 (222 acute; 188 stable); 48% male; mean
age = 65 (10); stable FEV-1 = 51% pred (20). Factor analyses
supported a unidimensional structure suitable for Rasch analysis.
Overall chi-square = 149.3 df = 84; person-separation index =
0.92. Three respiratory domains (breathlessness (5 items), cough-
sputum (2 items), chest symptoms (3 items)) account for 68% of
the variance; 4 items address systemic manifestations. Internal
consistency (Day 1, N = 410) total = 0.91; domains = 0.87; 0.69;
0.87. Reproducibility (ICC) in stable patients (n = 171) Day 1 to
7 = 0.77; 0.71; 0.65; 0.64. Correlation with SGRQ-C Day 1
(N = 395): r = 0.64; 0.66; 0.35; 0.46 (p < 0.0001). Signiﬁcant
differences in scores were found across exacerbation severity Day
1 (p < 0.001) and between responders and non-responders Days
1 to 10 (p < 0.0001). CONCLUSIONS: The EXAcerbations of
Chronic Pulmonary Disease Tool (EXACT) is a 14-item diary for
evaluating exacerbation outcomes of COPD with measurement
properties demonstrated to be adequate for use in clinical trials
with a similar population.
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INTERPRETING SCORES ONTHREE PATIENT-REPORTED
OUTCOME MEASURES FOR ASTHMA
Meads DM1,Twiss J1, McKenna SP1, Revicki D2, Pokrzywinski R3,
Gale R4
1Galen Research, Manchester, UK, 2United BioSource Corporation,
Bethesda, MD, USA, 3United Biosource Corporation, Pittsburgh, PA,
USA, 4Novartis AG, Horsham, UK
OBJECTIVES: To aid interpretation of scores on the Asthma
Life Impact Scale (ALIS; scored 0–22), COPD and Asthma Sleep
Impact Scale (CASIS; scored 0–100) and COPD and Asthma
Fatigue Scale (CAFS; scored 0–100). These new patient reported
outcome measures, designed for use in clinical trials, have pre-
viously been shown to be reliable and valid. METHODS: Ques-
tionnaire data from UK (n = 140; 29.3% male; mean age = 50.6
years) and US (n = 185; 25.9% male; mean age = 46.0 years)
surveys were analysed. Mean questionnaire scores were evalu-
ated against clinician severity rating and by exacerbation status
(US only). Effect sizes (ES) and standard errors of measurement
(SEM) gave a preliminary estimate of the minimal important
difference (MID). RESULTS: Scores on all three measures were
signiﬁcantly related to clinician rating of asthma severity
(p < 0.001) and patients who had had an exacerbation in the
previous week had signiﬁcantly (p < 0.05) worse scores on all
measures. For the ALIS the values for 0.3 ES, 0.5 ES and SEM
were 1.9, 3.2 and 1.7 respectively. For the CASIS the ﬁgures
were 5.3, 8.8 and 5.2 and for the CAFS; 7.2, 12.0 and 5.4.
Therefore these distribution-based analyses suggest that the
MID is in the region of two for the ALIS, ﬁve for the CASIS,
and seven for the CAFS. CONCLUSIONS: The analyses pro-
vide preliminary information on how to interpret scores on the
scales. Further analyses of longitudinal data are required
to conﬁrm these ﬁndings, to assess anchor-based estimates
and to allow greater precision in powering studies using these
questionnaires.
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HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS
OF A SURVEY IN 5 EUROPEAN COUNTRIES
Gueron B1, Freedman D2,Annunziata K2, Poterre M1
1GSK, Marly le Roi, France, 2Consumer Health Sciences, Princeton, NJ,
USA
OBJECTIVES: According to the GINA guidelines, asthma
control can be achieved and maintained in a majority of patients.
The 1999 AIRE study showed that only 5% of the adult asth-
matic patients were controlled. Several years later, how does
the situation look like? METHODS: Population based cross-
sectional survey was carried out in 2006 in France, Germany,
Italy, Spain, and the UK. A detailed questionnaire was adminis-
tered to a sample of adult individuals drawn from an Internet
panel. The Asthma Control Test (ACTTM) was used to assess the
level of control: Total Control (TC, score = 25), Well controlled
(WC, score = 20–24) and not well-controlled (NWC, score <20).
RESULTS: Among the 37,476 individuals who participated,
2,337 had been diagnosed with asthma by a physician. 80% used
rescue medication 2–3 times a week, 58% woke up once a week
due to asthma, 70% had shortness of breath 3–6 times /week.
Overall, 55% of asthmatic patients were not controlled despite
being treated, ranging from 45% to 72%. CONCLUSIONS:
This survey suggests the level of asthma control has improved
since AIRE. However, the majority of patients still remain uncon-
trolled. Further efforts are required to translate the GINA rec-
ommendations to prevent symptoms and ensure patients achieve
and maintain control into reality.
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SOCIOECONOMIC ANALYSIS OF SMOKER’S PROFILE WHO
INTENDSTO QUIT
Ramón JM1, Bruguera E2, Sanz de Burgoa V3, Ramírez E4
1Hospital de Bellvitge, Barcelona, Spain, 2Hospital Vall d’Hebron,
Barcelona, Spain, 3Laboratorios Pﬁzer, Alcobendas, Madrid, Spain,
4Infociencia S.L, Barcelona, Spain
OBJECTIVES: Depressed socio-cultural and economic groups
tend to smoke more than the others. We aimed to determine
socioeconomic level related aspects of the smoker’s proﬁle who
intends to stop smoking. METHODS: A total of 1634 smokers
older than 18, attended by General Practitioners and Specialized
Physicians in Spain, were included in a multicentric cross-
sectional survey study performed in February–June 2007. After
being asked about their intention of smoking cessation, all of
them were determined to or had taken some action to quit
smoking within the previous 15 days. Socio-demographic data,
taking into account socio-economic indicators, history of
smoking and reasons to stop smoking were collected. Descriptive
statistical analysis was performed. RESULTS: The analysed
population included 1618 subjects from 167 centers fulﬁlling all
the selection criteria. Their mean age was 45.6  12.0 and 56%
were men. The majority (67.8%) had studied beyond high school
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